134 related articles for article (PubMed ID: 36752325)
1. Mitragynine, a primary constituent of kratom reinstates morphine-seeking behaviour in rats.
Japarin RA; Harun N; Hassan Z; Shoaib M
Behav Pharmacol; 2023 Apr; 34(2-3):123-130. PubMed ID: 36752325
[TBL] [Abstract][Full Text] [Related]
2. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.
Hemby SE; McIntosh S; Leon F; Cutler SJ; McCurdy CR
Addict Biol; 2019 Sep; 24(5):874-885. PubMed ID: 29949228
[TBL] [Abstract][Full Text] [Related]
3. The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.
Hiranita T; Leon F; Felix JS; Restrepo LF; Reeves ME; Pennington AE; Obeng S; Avery BA; McCurdy CR; McMahon LR; Wilkerson JL
Psychopharmacology (Berl); 2019 Sep; 236(9):2725-2734. PubMed ID: 31098655
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of Mitragyna speciosa extract, mitragynine, and opioid agonists on thermal nociception in rats.
Carpenter JM; Criddle CA; Craig HK; Ali Z; Zhang Z; Khan IA; Sufka KJ
Fitoterapia; 2016 Mar; 109():87-90. PubMed ID: 26688378
[TBL] [Abstract][Full Text] [Related]
5. Cross-reinstatement of mitragynine and morphine place preference in rats.
Japarin RA; Yusoff NH; Hassan Z; Müller CP; Harun N
Behav Brain Res; 2021 Feb; 399():113021. PubMed ID: 33227244
[TBL] [Abstract][Full Text] [Related]
6. Discriminative stimulus properties of mitragynine (kratom) in rats.
Harun N; Hassan Z; Navaratnam V; Mansor SM; Shoaib M
Psychopharmacology (Berl); 2015 Jul; 232(13):2227-38. PubMed ID: 25616583
[TBL] [Abstract][Full Text] [Related]
7. Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal.
Wilson LL; Chakraborty S; Eans SO; Cirino TJ; Stacy HM; Simons CA; Uprety R; Majumdar S; McLaughlin JP
Cell Mol Neurobiol; 2021 Jul; 41(5):1131-1143. PubMed ID: 33433723
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats.
Behnood-Rod A; Chellian R; Wilson R; Hiranita T; Sharma A; Leon F; McCurdy CR; McMahon LR; Bruijnzeel AW
Drug Alcohol Depend; 2020 Oct; 215():108235. PubMed ID: 32889450
[TBL] [Abstract][Full Text] [Related]
9. Effects of alkaloid-rich extract from Mitragyna speciosa (Korth.) Havil. on naloxone-precipitated morphine withdrawal symptoms and local field potential in the nucleus accumbens of mice.
Cheaha D; Reakkamnuan C; Nukitram J; Chittrakarn S; Phukpattaranont P; Keawpradub N; Kumarnsit E
J Ethnopharmacol; 2017 Aug; 208():129-137. PubMed ID: 28687506
[TBL] [Abstract][Full Text] [Related]
10. Mitragynine improves cognitive performance in morphine-withdrawn rats.
You CY; Hassan Z; Müller CP; Suhaimi FW
Psychopharmacology (Berl); 2022 Jan; 239(1):313-325. PubMed ID: 34693456
[TBL] [Abstract][Full Text] [Related]
11. Mitragynine (Kratom)-Withdrawal behaviour and cognitive impairments can be ameliorated by an epigenetic mechanism.
Yunusa S; Müller CP; Hassan Z
Br J Pharmacol; 2024 Jul; 181(13):2070-2084. PubMed ID: 38523471
[TBL] [Abstract][Full Text] [Related]
12. The effects of chronic mitragynine (Kratom) exposure on the EEG in rats.
Suhaimi FW; Hassan Z; Mansor SM; Müller CP
Neurosci Lett; 2021 Feb; 745():135632. PubMed ID: 33444671
[TBL] [Abstract][Full Text] [Related]
13. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy.
Harun N; Kamaruzaman NA; Mohamed Sofian Z; Hassan Z
Neurosci Lett; 2022 Mar; 773():136500. PubMed ID: 35114335
[TBL] [Abstract][Full Text] [Related]
14. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
[TBL] [Abstract][Full Text] [Related]
15. Respiratory effects of oral mitragynine and oxycodone in a rodent model.
Henningfield JE; Rodricks JV; Magnuson AM; Huestis MA
Psychopharmacology (Berl); 2022 Dec; 239(12):3793-3804. PubMed ID: 36308562
[TBL] [Abstract][Full Text] [Related]
16. Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
Avery BA; Boddu SP; Sharma A; Furr EB; Leon F; Cutler SJ; McCurdy CR
Planta Med; 2019 Mar; 85(4):340-346. PubMed ID: 30452072
[TBL] [Abstract][Full Text] [Related]
17. Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats.
Harun N; Johari IS; Mansor SM; Shoaib M
Psychopharmacology (Berl); 2020 Mar; 237(3):855-867. PubMed ID: 31832720
[TBL] [Abstract][Full Text] [Related]
18. Kratom policy: The challenge of balancing therapeutic potential with public safety.
Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
[TBL] [Abstract][Full Text] [Related]
19. Analgesic effects of main indole alkaloid of kratom, mitragynine in acute pain animal model.
Mat NH; Bakar SNS; Murugaiyah V; Chawarski MC; Hassan Z
Behav Brain Res; 2023 Feb; 439():114251. PubMed ID: 36503042
[TBL] [Abstract][Full Text] [Related]
20. Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats.
Sabetghadam A; Ramanathan S; Sasidharan S; Mansor SM
J Ethnopharmacol; 2013 Apr; 146(3):815-23. PubMed ID: 23422336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
